# Platbio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/platbio

- Industry: Biotechnology
- Headquarters: Suwon, South Korea
- Total disclosed funding: $2.8M
- Latest round: Series A (Jan 10, 2020)
- Investors on record: 4

## About

Based in Suwon, South Korea, and founded in 2018, Platbio Inc., a.k.a. Platbio operates as a biotechnology company focused on novel drug development using an innovative drug discovery platform. The company leverages a proprietary translational research approach to address unmet medical needs, particularly in cancer treatment. In October 2021, Platbio Inc. raised KRW 4.8 billion in a Series B funding from Kolon Group. The series B round values Platbio Inc. at KRW 64 billion post-money.

Platbio focuses on developing new drugs using its proprietary drug discovery platform, PRIINT™. This platform integrates advanced genomics and proteomics for the identification and isolation of novel therapeutic targets, particularly in oncology. Platbio utilizes orthotopic animal models to mimic tumor-environment interactions, providing a more accurate representation of human cancer for preclinical research. The company’s services include drug efficacy evaluation, therapeutic regimen development, and drug repositioning strategies. Platbio also offers CRO and consulting services for nonclinical and clinical development, aiming to streamline drug discovery and improve precision in translational research.

## Funding rounds

- Series A, Jan 10, 2020, $2.8M — Solidus Investment, LS Securities, Starquest Asset Management, Sneak Peek Investment

## Investors

- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series A
- LS Securities — Series A
- Starquest Asset Management — Series A
- Sneak Peek Investment (https://capitalatlas.ai/funds/sneak-peek-investment) — Series A